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Abstract
IgM paraproteins from patients with CANOMAD chronic ataxic neuropathy, ophthalmoplegia, M-protein, agglutination, anti-disialo-
.  .syl antibodies react with NeuAc a 2–8 NeuAc epitopes on a wide range of gangliosides including GQ1b, GT1a, GD1b and GD3. The
tissue distribution of reactive antigens in human peripheral nerve has not been addressed in detail. In addition, the origin of these
antibodies is unknown. Here we report that purified anti-disialosyl paraproteins from two affected patients bind a wide array of human
peripheral nerve structures including dorsal root ganglia, dorsal and ventral root axons, femoral and oculomotor nerves. We also show
that these paraproteins bind lipopolysaccharides of Campylobacter jejuni isolates from 3r3 cases of Miller Fisher syndrome, and to a less
frequent extent, from cases of Guillain-Barre syndrome and enteritis controls. In conjunction with our previous studies, these data provide´
a possible causal link between the origin and pathogenic effects of anti-disialosyl antibodies in human paraproteinaemic neuropathy.
q 1997 Elsevier Science B.V.
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1. Introduction
Phenotypic variants of autoimmune neuropathy are
characterised by specific patterns of serum anti-ganglioside
antibodies. One form of peripheral neuropathy associated
with such an unique pattern of anti-ganglioside antibodies
is an IgM paraproteinaemic neuropathy with core clinical
features of chronic sensory ataxia and areflexia and with
variably present ophthalmoplegia andror red blood cell
 . cold agglutinating cold agglutinin activity Ilyas et al.,
1985; Arai et al., 1992; Duane et al., 1992; Obi et al.,
1992; Yuki et al., 1992; Willison et al., 1993a; Herron et
.al., 1994; Brindel et al., 1994 . This has recently been
reported under the acronym CANOMAD: chronic ataxic
neuropathy with ophthalmoplegia, M-protein, agglutination
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 .and disialosyl antibodies Willison et al., 1996 . The IgM
paraproteins found in patients with CANOMAD react with
 .  .NeuAc a 2–8 NeuAc a 2–3 Gal disialosyl epitopes pre-
sent on a wide range of neural gangliosides including
GQ1b, GT1a, GT1b, GD1b, GD3 and GD2. This or a
structurally similar epitope is also present on red blood cell
glycophorins, thereby accounting for the concurrent cold
agglutinin disease due to red cell cold agglutinating activ-
ity of anti-Pr specificity in some CANOMAD cases
 .Roelcke and Kreft, 1984 .
Some CANOMAD patients have fixed or intermittent
episodes of ophthalmoplegia andror bulbar dysfunction
 .Ilyas et al., 1985; Brindel et al., 1994, Herron et al., 1994
 .reminiscent of Miller Fisher syndrome MFS , a variant of
 .Guillain-Barre syndrome GBS characterised by acute´
 .ataxia, areflexia and ophthalmoplegia Fisher, 1956 . Over
90% of acute phase MFS sera also contain anti-GQ1b and
anti-GT1a IgG antibodies Chiba et al., 1992, 1993; Yuki
.et al., 1993; Willison et al., 1993b which react with GD1b
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 .and GD3 in around half the cases O’Leary et al., 1996 .
Thus, in addition to sharing similar clinical features,
CANOMAD and MFS also share a similar pattern of
serum anti-ganglioside antibodies. In CANOMAD the anti-
bodies are of IgM class and chronically elevated, whereas
in MFS which is an acute and self limiting disease, the
antibodies are IgG, subclass restricted to IgG and IgG ,1 3
 .and transiently present Willison and Veitch, 1994 .
The distribution of immunoreactive epitopes identified
with CANOMAD sera in the human peripheral nervous
system has not been thoroughly examined. In the mouse,
we have shown that an IgM antibody cloned from an
affected patient binds to many peripheral structures includ-
 .ing dorsal root ganglion DRG neurons , sensory and
motor peripheral nerve trunks, motor nerve terminals and
 .muscle spindles Willison et al., 1996 . One previous study
using whole serum from a CANOMAD case has shown
IgM binding to human DRG neurons but no staining was
 .seen in other sites Oka et al., 1996 . In view of our studies
in the mouse this seems surprising. Other studies have
performed immunocytochemical localisation studies using
murine monoclonal antibodies raised by ganglioside immu-
nisation which have been selected for their high specificity
for individual gangliosides including GQ1b Chiba et al.,
.  .1993 and GD1b Kusonoki et al., 1993 . Although of
interest in their own right, these antibodies are neither
representative of the CANOMAD specificity, nor directly
comparable with human autoantibodies. Here we report
our findings that highly purified IgM paraproteins from
CANOMAD cases have broader tissue immunoreactivity
in man than previously recognised.
 .Campylobacter jejuni C. jejuni enteritis is a com-
monly recognised infection known to precipitate MFS and
several investigators have isolated strains of C. jejuni from
MFS subjects Yuki et al., 1994; Jacobs et al., 1995;
.Salloway et al., 1996 . Evidence indicates that anti-GQ1b
ganglioside antibody responses in MFS are triggered as a
result of molecular mimicry with structurally similar epi-
 .topes on lipopolysaccharides LPS from MFS-associated
strains of C. jejuni. Serological studies using anti-GQ1b
monoclonal antibodies and MFS sera have demonstrated
GQ1b-like epitopes on whole organisms and LPS from
strains of C jejuni isolated from patients with MFS Yuki
.et al., 1994; Jacobs et al., 1995, 1997 . Structural charac-
terisation of an MFS associated LPS core oligosaccharide
has shown it to contain a terminal trisaccharide comprising
 .  .NeuAc a 2–8 NeuAc a 2–3 Gal which is common to
 .GQ1b, GT1a and GD3 gangliosides Salloway et al., 1996 .
We therefore considered the possibility that the IgM para-
proteins found in CANOMAD sera might also arise through
antigenic stimulation by disialylated or polysialylated epi-
topes on core oligosaccharides of C. jejuni derived LPS.
Here, we tested the reactivities of highly purified mono-
clonal IgM fractions containing anti-disialosyl antibodies
from 2 CANOMAD patients with LPS from a panel of C.
jejuni isolates from patients with MFS, GBS and controls.
2. Materials and methods
2.1. Clinical subjects
 ..Clinical reports on patients VP Herron et al., 1994
 .and CH Willison et al., 1993a, 1996 have been previ-
ously published. Both had features of a chronic, predomi-
nantly sensory neuropathy comprising peripheral sensory
loss, profound limb ataxia, areflexia and mild or absent
limb weakness. Interspersed on the chronic background in
both patients recognised subsequent to the 1993 report in
.patient CH was episodic deterioration with craniobulbar
dysfunction, including ophthalmoplegia. Both patients had
IgM lambda paraproteins with anti-Pr cold agglutinating
 5.activity and very high titre )1r10 anti-disialylated
ganglioside antibodies, thereby comprising the
CANOMAD phenotype. To assess CANOMAD sera for
evidence of a recent C. jejuni infection, serum IgM, IgG,
and IgA antibodies against a glycine extract of C. jejuni
proteins were determined by ELISA, as previously de-
 .scribed Jacobs et al., 1996 .
2.2. Anti-ganglioside antibody assays and antibody purifi-
cation
Serum anti-ganglioside antibodies in CANOMAD pa-
 .tients VP, CH and in neuropathy subjects A–F from
whom C. jejuni strains were isolated were determined by
 .enzyme linked immunosorbent assay ELISA and thin
 .layer chromatography overlay TLC overlay using a panel
of commercially available gangliosides as previously de-
 .scribed Willison et al., 1993a . IgM cold agglutinating
antibodies from VP and CH were affinity purified from
plasma by temperature-dependent elution on human group
 . O red blood cells RBC , as previously described Willison
.et al., 1993a . These fractions were monitored by quantita-
 .tive immunoassay for IgM and isoelectric focusing IEF
with western blotting as previously described for CH and
 .are referred to as rbc-M Willison et al., 1996 .
2.3. Campylobacter jejuni isolates and lipopolysaccharide
extraction
The characteristics of the C. jejuni strains and subjects
from whom they were derived are shown in Table 1.
Organisms were isolated from stool cultures of 3 patients
 .  .with MFS A, B and C , 3 patients with GBS D, E and F
and 3 enteritis patients without neurological involvement
 .  .1, 2 and 3 , as described previously Jacobs et al., 1997 .
Patient A, B and C had clinical features of ophthalmople-
gia, ataxia and areflexia without limb weakness, and pa-
tients D, E and F fulfilled the diagnostic criteria for GBS.
C. jejuni bacteria were grown on blood agar plates in a
microaerobic atmosphere. After 48 h the bacteria were
harvested, inactivated in 1% formaldehyde and washed in
 .  .phosphate-buffered saline solution PBS pH 7.4 . The
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Table 1
Serotypes of C. jejuni isolates and antibody profiles of neuropathy and
enteritis control subjects from whom they were derived
Subject Diagnosis Anti-ganglioside C. jejuni serotype
 .antibody profile Penner
A MFS GQ1b,GD1b, GD3 O:4,50
B MFS GQ1b non-typable
C MFS GQ1b,GD1b, GD3 O:23
D GBS GM1, GD1b O:1
E GBS none detected O:24
F GBS not tested non-typable
1 enteritis not tested O:23
2 enteritis not tested O:22
3 enteritis not tested O:41
LPS fractions from the C. jejuni bacteria were isolated by
 .phenol–water extraction Westphal and Jahn, 1965 and
were demonstrated to contain less than 1% proteins. For
control studies the LPS fractions were incubated with 0.05
Urml of sialidase from Clostridium perfringens or
 .Arthrobacter ureafaciens Sigma, St. Louis, MO in 50
 .mM of sodium acetate buffer pH 5.5 overnight at 378C.
After incubation, the LPS were incubated at 808C for 30
min to inactivate the sialidases.
2.4. Detection of antibodies reacti˝e with lipopolysaccha-
rides
IgM antibodies against LPS were tested by ELISA and
TLC-overlay. ELISA was performed by coating 96-well
polystyrene microtiter trays Immuno Maxisorb, Nunc,
.Roskilde with 1 mg of LPS in 50 ml PBS per well
overnight. After the coating all steps were performed at
48C. Non-specific binding sites were blocked with PBS
 .containing 1% bovine serum albumin BSA for 4 h. After
blocking, the plates were incubated with 0.1 to 10 mgrml
rbc-M from VP or CH in PBS–0.1% BSA overnight. After
washing with PBS, the plates were incubated with peroxi-
 .dase-conjugated goat antihuman IgM mu-chain specific
diluted 1:2500 in PBS–0.1% BSA for 4 h. After washing
with PBS, the plates were developed with O-phenyl di-
 .  .amine Sigma in citrate buffer pH 5.0 and the optical
densities were read at 490 nm. TLC was performed on
aluminium backed Kieselgel 60 WF254S high-perfor-
 .mance TLC plates Merck, Darmstadt loaded with 7 mg of
 .LPS in methanolrwater 4:1, by volume , and developed
 .in n-propanolrwaterr25% NH OH 24:12:8, by volume .4
After chromatography, the plates were air-dried and dipped
in a solution of 0.1% polyisobutylmethacrylate in n-hexane.
The overlays and washings were performed at 48C. The
plates were air-dried and blocked with PBS-1% BSA for 1
h and incubated with 0.1 to 10 mgrml of rbc-M in
PBS–0.1% BSA for 4 h. After washing with PBS, the
plates were incubated for 2 h. with peroxidase-conjugated
 .goat–anti-human IgM mu-chain specific, Sigma in PBS-
0.1% BSA and washed with PBS. The plates were devel-
oped for 10–150 s using enhanced chemiluminescence
 .ECL, Amersham .
2.5. Immunofluorescence studies
 .Human spinal cord, dorsal root ganglia DRG , dorsal
and ventral roots, femoral nerve and 3rd cranial nerve were
obtained from a middle aged male without neurological
disease at post mortem subject to local ethical approval
and guidelines. Tissues embedded in Tissue-Tek O.C.T.
 .mounting medium Miles Diagnostics, Elkhart, IN were
frozen in a slurry of ethanol and dry-ice and stored at
 .y708C. Cryostat sections 5–15 m were cut onto 3-
 .aminopropyltriethoxysilane APES coated slides, and al-
lowed to air-dry before immediate use or storage at y208C.
Mounted tissue sections were incubated with the rbc-M
fractions from VP and CH at 40 mgrml, diluted in PBS
containing 10% goat serum and 0.1% Triton X100 for 3 h
at 48C. Mouse anti-neurofilament antibody clone 1217,
.Affiniti Research Products, Exeter was used at 1:1000
dilution. After primary antibody incubations, sections were
drained, rinsed in four washes of cold PBS and incubated
with rhodamine labelled goat anti-human IgM and fluores-
cein labelled goat anti-mouse IgG secondary antibodies
 .Southern Biotechnology at 1:300 dilutions in staining
medium for 1 h at 48C. The slides were again rinsed =4 in
cold PBS before being mounted in Citifluor antifade
 .Citifluor, Canterbury , ringed with nail-varnish to min-
imise drying and stored at 48C in the dark prior to viewing.
Consistent fluorescence signals were totally dependent on
strict maintenance of all solutions at 48C at all times
throughout the staining procedure.
Sections were also stained with the anti-neurofilament
antibody plus an irrelevant human IgM monoclonal anti-
body andror secondary anti-human IgM antibody to con-
trol for non-specific binding and fluorescence bleed-
through between detection channels: the threshold of the
image acquisition equipment was calibrated such that the
control level of staining was at or close to zero. Images
were obtained by means of a Sony colour CCD camera
mounted onto a Zeiss Axioplan fluorescent microscope
and linked to a PC driven image archiving system Sirrius
.VI; Optivision . Bitmap processing and annotation were
conducted on PhotoMagic and Windows Draw both by
.Micrographx . Images were printed directly using a photo-
 .graphic-quality colour printer Kodak ColorEase .
3. Results
3.1. Serological studies on CANOMAD subjects
Patients VP and CH had anti-ganglioside IgM antibody
titres previously reported as follows. For VP: GM1, -100;
GM2, 30,000; GM3, - 100; GD1a, 30,000; GD1b,
120,000; GT1b, 100,000; GQ1b, 170,000; GD3 150,000.
For CH: GM1, -100; GM2, -100; GM3, 660; GD1a,
570; GD1b, 850,000; GT1b, 300,000; GQ1b, 450,000;
GD3 260,000. The rbc-M fractions in both patients had an
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 .Fig. 1. Western blots of IEF gels of whole serum lanes 1 and 3 and
 .  .  .rbc-M lanes 2 and 4 from VP lanes 1 and 2 and CH lanes 3 and 4
stained with anti-human IgM showing the monoclonal IgM on a back-
ground of polyclonal IgM in serum compared with the pure paraprotein
of identical isoelectric mobility in rbc-M. Monoclonal immunoglobulins
appear as ladders in IEF gels due to charge micro-heterogeneity.
identical pattern of anti-ganglioside antibody reactivity as
 .the sera from which they were derived data not shown .
 .IEF western blotting of serum and rbc-M Fig. 1 showed
resolution of the rbc-M as a pure monoclonal ladder
corresponding to the serum monoclonal IgM and free of
polyclonal IgM when compared with the IEF profile of
whole serum. No antibody reactivity against a C. jejuni
glycine extract was detected in either whole serum or
rbc-M from VP and CH, indicating no recent C. jejuni
infection.
3.2. Reacti˝ity of rbc-M fractions from CH and VP with C.
jejuni lipopolysaccharides
The rbc-M fractions from VP and CH bound with LPS
from the C. jejuni isolates from all 3 MFS patients sub-
.  .jects A, B and C , and from one GBS patient subject E
 .and one enteritis control subject 3 as shown in Fig. 2.
These patterns of binding were confirmed in TLC-overlay
in which LPS from MFS A, B and C, GBS E and enteritis
control 3 were positive and LPS from GBS D and F and
 .enteritis controls 1 and 2 were negative Fig. 3 . Binding
of rbc-M from VP and CH to LPS was found to be higher
at 48C than at 378C incubation as was also previously seen
 .for ganglioside binding data not shown . The capacity of
the LPS to bind rbc-M from both VP and CH decreased
after treatment of the LPS with sialidases from Clostrid-
 .ium perfringens Fig. 2 and Arthrobacter ureafaciens
 .data not shown . No activity was demonstrated against
LPS from the C. jejuni isolates of GBS subjects D and F
and control subjects 1 and 2. There was no obligate
association between the presence of the paraprotein bind-
ing epitopes on LPS and the Penner serotype of the
bacteria: enteritis control 1 is Penner O:23 and does not
bind the paraproteins, although it has the same O:23
Fig. 2. ELISA analysis of the reactivity of rbc-M from patients VP 1
.  .mgrml; panel A and CH 10 mgrml; panel B with LPS from C. jejuni
 .  .isolates without hatched bars and with solid bars treatment with
Clostridium perfringens neuraminidase. LPS from all 3 MFS-associated
 .C. jejuni strains lanes A, B and C are reactive compared with LPS from
 .one of the GBS-associated C. jejuni strains lanes D, E and F and one
 .enteritis control strain lanes 1, 2 and 3 . Meansq2SD.
serotype as the isolates from MFS patient C, which does
bind the paraproteins.
3.3. Immunofluorescence studies on human peripheral
ner˝e
The binding patterns of rbc-M from VP and CH to a
wide range of human peripheral nerve structures were
identical. In spinal cord, the rbc-M bound amorphously to
grey matter including weak cytoplasmic labelling of mo-
 .Fig. 3. TLC-overlay analysis of LPS 7 mgrlane from 3 MFS-associated
 .C. jejuni strains panels A, B and C and 2 of the GBS-associated C.
 .jejuni strains panels D and E immunostained with rbc-M from patient
 .CH 10 mgrml . Reactivity patterns correspond to those seen with
ELISA.
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torneuron cell bodies. There was very faint binding to
 .white matter tracts. In the DRG Fig. 4 the majority of
neuronal cell bodies displayed granular staining of an area
including, and extending slightly beyond the neurofila-
 .ment-positive region Fig. 4, panels a and b , although a
small population were unstained. In some areas of the
DRG there was also weaker staining of extracellular re-
gions surrounding the cell bodies. In fibre bundles within
the DRG, there was strong staining associated with the
 .axons of large fibres Fig. 4, panels c and d , little or no
staining of the myelin sheath, and surrounding haloes of
 .staining in the extra cellular space Fig. 4, panels e and f .
Strong labelling of blood vessel walls was seen throughout
the nervous system, here shown in the DRG Fig. 4, panel
.  .d, arrow . In the spinal roots Fig. 5, panels a and b , both
the dorsal and ventral root large fibre axons and surround-
ing extracellular regions were similarly stained, with little
labelling evident in their compact myelin sheaths. A simi-
lar pattern was observed in the 3rd cranial nerve Fig. 5,
.panels c and d . Large fibres in the femoral nerve were
 .Fig. 4. Double-labelled pairs of fluorescent micrographs showing the immunolocalisation of rbc-M panels b, d and f and anti-neurofilament antibodies
 .  .panels a, c and e in human dorsal root ganglion. The majority of cell bodies are labelled panels a and b; bars50 mm . In fibre bundles within the DRG
 .staining was localised to axonal profiles, connective tissue and blood vessels arrow; panels c and d; bars50 mm . At higher magnification, labelling of
 .large axons and the extracellular regions surrounding their myelin sheaths is seen panels e and f; bars20 mm .
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also stained in this pattern. Longitudinal sections con-
firmed this pattern and did not show significant compact or
paranodal myelin staining. Small diameter fibre bundles in
the femoral nerve, identifiable by clusters of neurofilament
positive profiles were strongly immunoreactive Fig. 5,
.panels e and f although it was not possible to identify
specific structures within the bundles at this resolution.
These small fibre bundles were also readily identifiable
within the dorsal root but were absent as expected from
.the fibre size distribution in the ventral root.
4. Discussion
In these studies we have shown that IgM paraproteins
from patients with CANOMAD share immunoreactive de-
terminants with human peripheral nerve antigens and C.
jejuni LPS derived from MFS patients. These data provide
a possible pathogenic link between the origin and the
effect of anti-disialylated ganglioside IgM paraproteins in
humans. They and also add further support to the view that
CANOMAD and MFS are related polyneuropathies, char-
 .Fig. 5. Double-labelled pairs of fluorescent micrographs showing the immunolocalisation of rbc-M panels b, d and f and anti-neurofilament antibodies
 .  .panels a, c and e in human peripheral nerve. Axonal profiles and extracellular regions are stained in the ventral root panels a and b; bars20 mm and
 .  .3rd cranial nerve panels c and d; bars10 mm . In the femoral nerve staining is intense over small fibre bundles panels e and f; bars20 mm .
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acterized by anti-ganglioside antibodies with overlapping
but distinct specificity.
All MFS sera that bind GQ1b also bind GT1a and 50%
of these MFS sera also bind other gangliosides bearing at
 .least one NeuNAc a 2–8 NeuNAc- residue, such as GD1b
 .and GD3 Willison et al., 1994 . The specificity of
CANOMAD paraproteins for gangliosides is broader in
that both the paraproteins described here bind to all Ne-
 .uNAc a 2–8 NeuNAc- bearing gangliosides we have stud-
ied and may also bind very weakly to other gangliosides
including GD1a and GM2 Willison et al., 1993a; Herron
.et al., 1994 . Anti-GQ1b antibodies in sera from MFS
patients and murine monoclonal anti-GQ1b antibodies re-
act with C. jejuni LPS derived from MFS cases, indicating
that these LPS molecules bear a GQ1b-like epitope Yuki
.et al., 1994; Jacobs et al., 1995 . Interestingly the LPS core
oligosaccharide from the only MFS associated C. jejuni to
be structurally chacterised to date bears a GD3-like termi-
nal trisaccharide rather than a GQ1b or GT1a motif Sallo-
.  .way et al., 1996 . In addition, Aspinall et al. 1994 have
reported the structure of a GBS-associated LPS as contain-
ing a GT1a-like motif. It would thus appear that there may
not be an exact relationship between the LPS oligosaccha-
ride structure and the fine specificity of the corresponding
anti-ganglioside antibody serology. Our data show that
CANOMAD paraproteins not only react with LPS from all
3 MFS-associated C. jejuni strains but also bound 1r3
GBS strains and 1r3 control strains, which were not
 .bound by MFS sera Jacobs et al., 1997 . This indicates
that CANOMAD paraproteins have a broader specificity
for sialidase sensitive LPS structures than MFS sera and
thus may arise through an immune response to a wider
range of disialylated LPS structures than MFS associated
antibodies.
There is no direct evidence that the paraproteins in
CANOMAD have arisen in response to C. jejuni LPS.
Neither of the CANOMAD cases reported enteritis as an
initiating event at the onset of neurological symptoms as is
seen in MFS. Equally, neither of the CANOMAD sera
contained any detectable antibodies to C. jejuni protein
antigens as assessed by routine C. jejuni serology: this
indicates that any infection is currently inactive and any
putative infection must have occurred in the distant past
such that serum antibody levels have now decayed to
sub-detectable levels. Our V region sequencing studies on
the paraprotein which we have cloned from patient CH
have shown that the antibody is encoded by immuno-
globulin variable region genes with extensive somatic mu-
tation; this is indicative of an origin through antigen driven
maturation rather than dysregulated proliferation of a naive
B-cell with a random antigen specificity as the primary
 .event Willison et al., 1996 . The appearance of parapro-
teins in CANOMAD would be consistent with an antigen
specific response to bacterial LPS, possibly chronically
sequestered in gut associated lymphoid tissue and possibly
arising from C. jejuni or other infections with cross reac-
tive motifs. Assuming that MFS-associated anti-GQ1b an-
tibodies and CANOMAD paraproteins arise in response to
C. jejuni LPS, the major difference is that the former
comprises an acute, self limiting primary immune response
with class switching from IgM to higher affinity IgG
antibodies whereas the latter comprises a chronic accumu-
lation of IgM produced by a slowly expanding dysregu-
lated clone of B cells.
We have already demonstrated in the MF1 mouse that
monoclonal CANOMAD paraproteins can bind widely to
murine peripheral nerve structures including dorsal root
ganglia, motor nerve terminals, peripheral nerve axons and
myelin and nodes of Ranvier. In addition, the paraprotein
can immunolocalise to and induce electrophysiological
abnormalities in motor nerve terminals in the ex vivo
hemi-diaphragm model of nerve transmission, selected for
study as one site out of many in the peripheral nerve unit
that could be pathologically affected in the human disease
 .Willison et al., 1996 . In our immunolocalisation studies
in the human peripheral nervous system described here we
have shown widespread binding to sensory and motor
nerves, including the 3rd cranial nerve, with prominent
staining in groups of dorsal root ganglion neurons. In view
of the sensory ataxia seen in CANOMAD cases, the dorsal
root ganglion, a site with a limited blood nerve barrier into
which antibody can easily penetrate, seems a likely target
for immunopathological attack. We have also observed
extensive extracellular binding which would be unlikely to
represent binding to gangliosides in this site but may
represent binding to sialylated extracellular matrix compo-
nents. The pattern of binding to human DRG neurons we
have seen with CANOMAD monoclonal paraproteins is
similar to that seen in previous reports using anti-GD1b
antibodies. Using a murine anti-GD1b monoclonal anti-
 .body, Kusonoki et al. 1993 have immunolocalised GD1b
to dorsal root ganglion neuronal cytoplasm and spinal root
 .axons. In studies by Oka et al. 1996 , using an unpurified
CANOMAD serum of very similar specificity to those
used here, a granular pattern of binding was seen in the
DRG neuronal cell bodies, again very similar to that seen
in this study. However, they observed no staining else-
where in peripheral nerve in marked contrast to our
CANOMAD IgM antibodies which stain human dorsal and
ventral roots and peripheral nerve axons extensively. Thus,
assuming that technical factors have not created the differ-
ence between our study and that of Oka and colleagues,
there must be critical differences in antibody fine speci-
ficity which dictate immunoreactivity in different periph-
eral nerve regions. These may be reflected by clinical
differences between patients.
Combined data from this and our previous studies sug-
gest the following pathophysiological sequence of events
 .in the evolution of CANOMAD: a individuals are in-
fected with C. jejuni or other pathogens bearing disialy-
 .lated ganglioside-like epitopes, b a low level, low affinity
IgM response is mounted with insufficient autopathogenic
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 .potential to cause an acute post-infectious neuropathy, c
transformation from a state of antigen dependent B cells
proliferation to autonomous B cell proliferation occurs,
 .with the formation of a monoclonal IgM gammopathy, d
serum IgM antibody levels rise to a level at which binding
kinetics favour sufficient antibody ‘on’ time to activate
pro-inflammatory pathways in target membranes of the
DRG and other antigen rich sites.
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